Application of a Biomimetic Nanoparticle-Based Mock Virus to Determine SARS-CoV-2 Neutralizing Antibody Levels in Blood Samples Using a Lateral Flow Assay DOI Creative Commons
Silvia Schobesberger,

Helena Thumfart,

Florian Selinger

et al.

Analytical Chemistry, Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 9, 2024

The presence of neutralizing antibodies against SARS-CoV-2 in blood, acquired through previous infection or vaccination, is known to prevent the (re)occurrence outbreaks unless virus mutates. Therefore, measurement constitutes an indispensable tool assessing individual's and a population's immunity SARS-CoV-2. For this reason, we have developed innovative lateral flow assay (LFA) capable detecting blood-derived using biomimetic mock system. Here, functionalized gold nanoparticles (AuNPs) featuring trimeric spike (S) protein at its surface imitate virus's structure are applied monitor efficacy blood samples. detection principle relies on interaction between immobilized angiotensin-converting enzyme 2 (ACE2) receptor, which inhibited when present. To further enhance sensitivity our competitive identify low titers antibodies, additional mixing pad embedded into device increase time antibodies. LFA benchmarked WHO International Standard (21/338) demonstrated reliable quantification that inhibit ACE2 binding events down limit antibody titer 59 IU/mL. Additional validation whole plasma samples showed reproducible results good comparability laboratory-based reference test, thus highlighting applicability for point-of-care testing.

Language: Английский

Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies DOI Open Access
Pia Gattinger, Anna Ohradanova‐Repic, Rudolf Valenta

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(6), P. 5352 - 5352

Published: March 10, 2023

More than three years ago, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused unforeseen COVID-19 pandemic with millions of deaths. In meantime, SARS-CoV-2 has become endemic and is now part repertoire viruses causing seasonal severe respiratory infections. Due to several factors, among them development immunity through natural infection, vaccination current dominance seemingly less pathogenic strains belonging omicron lineage, situation stabilized. However, challenges remain possible new occurrence highly variants remains a threat. Here we review development, features importance assays measuring neutralizing antibodies (NAbs). particular focus on in vitro infection molecular interaction studying binding receptor domain (RBD) its cognate cellular ACE2. These assays, but not measurement SARS-CoV-2-specific per se, can inform us whether produced by convalescent or vaccinated subjects may protect against thus have potential predict risk becoming newly infected. This information extremely important given fact that considerable number subjects, vulnerable persons, respond poorly production antibodies. Furthermore, these allow determine evaluate virus-neutralizing capacity induced vaccines administration plasma-, immunoglobulin preparations, monoclonal antibodies, ACE2 synthetic compounds be used for therapy assist preclinical evaluation vaccines. Both types relatively quickly adapted emerging virus about magnitude cross-neutralization, which even estimate infected appearing variants. Given paramount discuss their specific features, advantages disadvantages, technical aspects yet fully resolved issues, such as cut-off levels predicting degree vivo protection.

Language: Английский

Citations

20

Application of a Biomimetic Nanoparticle-Based Mock Virus to Determine SARS-CoV-2 Neutralizing Antibody Levels in Blood Samples Using a Lateral Flow Assay DOI Creative Commons
Silvia Schobesberger,

Helena Thumfart,

Florian Selinger

et al.

Analytical Chemistry, Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 9, 2024

The presence of neutralizing antibodies against SARS-CoV-2 in blood, acquired through previous infection or vaccination, is known to prevent the (re)occurrence outbreaks unless virus mutates. Therefore, measurement constitutes an indispensable tool assessing individual's and a population's immunity SARS-CoV-2. For this reason, we have developed innovative lateral flow assay (LFA) capable detecting blood-derived using biomimetic mock system. Here, functionalized gold nanoparticles (AuNPs) featuring trimeric spike (S) protein at its surface imitate virus's structure are applied monitor efficacy blood samples. detection principle relies on interaction between immobilized angiotensin-converting enzyme 2 (ACE2) receptor, which inhibited when present. To further enhance sensitivity our competitive identify low titers antibodies, additional mixing pad embedded into device increase time antibodies. LFA benchmarked WHO International Standard (21/338) demonstrated reliable quantification that inhibit ACE2 binding events down limit antibody titer 59 IU/mL. Additional validation whole plasma samples showed reproducible results good comparability laboratory-based reference test, thus highlighting applicability for point-of-care testing.

Language: Английский

Citations

2